Schechter Adam H 4

What Happened

• Adam H. Schechter, President & CEO and a director of Labcorp Holdings, was granted two awards on Feb 10, 2026: 31,700 employee stock options and 10,440 restricted stock units (RSUs). The Form 4 reports $0.00 as the acquisition price for both awards (typical for grants); the filing treats these as derivative awards rather than open‑market purchases or sales.
• The 31,700 instruments are stock options (the right to buy shares) granted under the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan. The 10,440 items are RSUs (each representing the contingent right to receive one share). These awards are part of executive compensation, not a market purchase.

Key Details

• Transaction date: 2026-02-10; Form 4 filed: 2026-02-12 (filed within the typical two-business-day window).
• Reported amounts: 31,700 options; 10,440 RSUs. Reported acquisition price on the Form 4: $0.00 (grant).
• Vesting: Options vest in three equal annual installments beginning on the date reflected (per footnote); RSUs vest in three equal annual installments beginning Feb 10, 2027.
• Plan: Options granted pursuant to the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan.
• Footnotes: F1 = employee stock option grant; F2 = option vesting schedule; F3 = RSU = right to one share; F4 = RSU vesting start; F5 = 10,440 reflects the aggregate number of RSUs held by the reporting person.
• Shares owned after the transaction and the options’ strike price are not shown in the provided excerpt of the Form 4.

Context

• These are grants (awards), not purchases or sales. Options give the right to buy shares in the future; RSUs convert to shares only as they vest. Such awards are commonly part of executive compensation and do not by themselves indicate immediate insider buying or selling activity.